SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Perinatal outcomes after selective third-trimester ultrasound screening for small-for-gestational age: prospective cohort study nested within DESiGN randomized controlled trial.

Winsloe, C; Elhindi, J; Vieira, MC; Relph, S; Arcus, CG; Coxon, K; Briley, A; Johnson, M; Page, LM; Shennan, A; et al. Winsloe, C; Elhindi, J; Vieira, MC; Relph, S; Arcus, CG; Coxon, K; Briley, A; Johnson, M; Page, LM; Shennan, A; Marlow, N; Lees, C; Lawlor, DA; Khalil, A; Sandall, J; Copas, A; Pasupathy, D; on behalf of the DESiGN Trial Team (2024) Perinatal outcomes after selective third-trimester ultrasound screening for small-for-gestational age: prospective cohort study nested within DESiGN randomized controlled trial. Ultrasound Obstet Gynecol. ISSN 1469-0705 https://doi.org/10.1002/uog.29130
SGUL Authors: Khalil, Asma

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (280kB) | Preview
[img] Microsoft Word (.docx) (Tables S1-S2) Supplemental Material
Download (221kB)

Abstract

OBJECTIVE: In screening for small-for-gestational age (SGA) using third-trimester antenatal ultrasound, there are concerns about the low detection rates and potential for harm caused by both false-negative and false-positive screening results. Using a selective third-trimester ultrasound screening program, this study aimed to investigate the incidence of adverse perinatal outcomes among cases with (i) false-negative compared with true-positive SGA diagnosis and (ii) false-positive compared with true-negative SGA diagnosis. METHODS: This prospective cohort study was nested within the UK-based DESiGN trial, a prospective multicenter cohort study of singleton pregnancies without antenatally detected fetal anomalies, born at > 24 + 0 to < 43 + 0 weeks' gestation. We included women recruited to the baseline period, or control arm, of the trial who were not exposed to the Growth Assessment Protocol (GAP) intervention and whose birth outcomes were known. Stillbirth and major neonatal morbidity were the two primary outcomes. Minor neonatal morbidity was considered a secondary outcome. Suspected SGA was defined as an estimated fetal weight (EFW) < 10th percentile, based on the Hadlock formula and fetal growth charts. Similarly, SGA at birth was defined as birth weight (BW) < 10th percentile, based on UK population references. Maternal and pregnancy characteristics and perinatal outcomes were reported according to whether SGA was suspected antenatally or not. Unadjusted and adjusted logistic regression models were used to quantify the differences in adverse perinatal outcomes between the screening results (false negative vs true positive and false positive vs true negative). RESULTS: In total, 165 321 pregnancies were included in the analysis. Fetuses with a false-negative SGA screening result, compared to those with a true-positive result, were at a significantly higher risk of stillbirth (adjusted OR (aOR), 1.18 (95% CI, 1.07-1.31)), but at lower risk of major (aOR, 0.87 (95% CI, 0.83-0.91)) and minor (aOR, 0.56, (95% CI, 0.54-0.59)) neonatal morbidity. Compared with a true-negative screening result, a false-positive result was associated with a lower BW percentile (median, 18.1 (interquartile range (IQR), 13.3-26.9)) vs 49.9 (IQR, 30.3-71.7)). A false-positive result was also associated with a significantly increased risk of stillbirth (aOR, 2.24 (95% CI, 1.88-2.68)) and minor neonatal morbidity (aOR, 1.60 (95% CI, 1.51-1.71)), but not major neonatal morbidity (aOR, 1.04 (95% CI, 0.98-1.09)). CONCLUSIONS: In selective third-trimester ultrasound screening for SGA, both false-negative and false-positive results were associated with a significantly higher risk of stillbirth, when compared with true-positive and true-negative results, respectively. Improved SGA detection is needed to address false-negative results. It should be acknowledged that cases with a false-positive SGA screening result also constitute a high-risk population of small fetuses that warrant surveillance and timely birth. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

Item Type: Article
Additional Information: © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology. This is an open access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: antenatal diagnosis, cerebral intraventricular hemorrhage, fetal death, fetal growth restriction, fetal weight, hypoxia–ischemia, brain, missed diagnosis, perinatal mortality, pregnancy complications, prenatal ultrasonography, on behalf of the DESiGN Trial Team, 1114 Paediatrics and Reproductive Medicine, Obstetrics & Reproductive Medicine
SGUL Research Institute / Research Centre: Academic Structure > Cardiovascular & Genomics Research Institute
Academic Structure > Cardiovascular & Genomics Research Institute > Vascular Biology
Journal or Publication Title: Ultrasound Obstet Gynecol
ISSN: 1469-0705
Language: eng
Dates:
DateEvent
25 November 2024Published Online
9 October 2024Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
UNSPECIFIEDTommy's Baby Charityhttps://doi.org/10.13039/501100000306
RG1011/16Stillborn and Neonatal Death Charityhttps://doi.org/10.13039/100011243
MAJ150704Guy's & St Thomas' FoundationUNSPECIFIED
BEX 9571/13–2CAPESUNSPECIFIED
UNSPECIFIEDNational Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South LondonUNSPECIFIED
MC_UU_00032/05Medical Research Councilhttp://dx.doi.org/10.13039/501100000265
CH/F/20/90003British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
AA/18/1/34219British Heart Foundationhttp://dx.doi.org/10.13039/501100000274
NF-0616-10102National Institute for Health Researchhttp://dx.doi.org/10.13039/501100000272
PubMed ID: 39586022
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/116984
Publisher's version: https://doi.org/10.1002/uog.29130

Actions (login required)

Edit Item Edit Item